New hope for stem cell transplant patients facing deadly blood clot disorder

NCT ID NCT04543591

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 30 times

Summary

This study tested a drug called ravulizumab in 148 people aged 12 and older who developed a serious blood clotting condition (thrombotic microangiopathy) after a stem cell transplant. The goal was to see if the drug could improve survival and prevent the condition from getting worse. Participants received either ravulizumab or a placebo along with standard care for 26 weeks, followed by 26 weeks of monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Grosse Pointe Farms, Michigan, 48236, United States

  • Research Site

    Durham, North Carolina, 27705, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    Seattle, Washington, 98109, United States

  • Research Site

    Parkville, 3050, Australia

  • Research Site

    Bruges, 8000, Belgium

  • Research Site

    Brussels, 1200, Belgium

  • Research Site

    Chênée, 4032, Belgium

  • Research Site

    Yvoir, 5530, Belgium

  • Research Site

    Cerqueira César, 05403-000, Brazil

  • Research Site

    Florianópolis, 88034-000, Brazil

  • Research Site

    Jaú, 17210-080, Brazil

  • Research Site

    Porto Alegre, 90035-903, Brazil

  • Research Site

    Porto Alegre, 90110-270, Brazil

  • Research Site

    Rio de Janeiro, 20230-130, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 05.403-010, Brazil

  • Research Site

    Calgary, Alberta, T2N 4N1, Canada

  • Research Site

    Suzhou, 215006, China

  • Research Site

    Tianjin, 300020, China

  • Research Site

    Angers, 49033, France

  • Research Site

    La Tronche, 38043, France

  • Research Site

    Nice, 06200, France

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    Ulm, 89081, Germany

  • Research Site

    Athens, 12462, Greece

  • Research Site

    Pátrai, 26504, Greece

  • Research Site

    Thessaloniki, 57010, Greece

  • Research Site

    Halfa, 31096, Israel

  • Research Site

    Ramat Gan, 52621, Israel

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Udine, 33100, Italy

  • Research Site

    Akita, 010-8543, Japan

  • Research Site

    Anjo, 446-8602, Japan

  • Research Site

    Chiba, 260-8677, Japan

  • Research Site

    Fukushima, 960-1295, Japan

  • Research Site

    Isehara-shi, 259-1193, Japan

  • Research Site

    Kurashiki-shi, 710-8602, Japan

  • Research Site

    Minatoku, 105-8470, Japan

  • Research Site

    Okayama, 700-8558, Japan

  • Research Site

    Osaka, 545-8586, Japan

  • Research Site

    Osakasayama-shi, 589-8511, Japan

  • Research Site

    Sapporo, 060-8638, Japan

  • Research Site

    Suita-shi, 565-0871, Japan

  • Research Site

    Tsukuba, 305-8576, Japan

  • Research Site

    Wakayama, 641-8510, Japan

  • Research Site

    Groningen, 9713 GZ, Netherlands

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Granada, 18014, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Huddinge, 141 57, Sweden

  • Research Site

    London, W12 0HS, United Kingdom

  • Research Site

    Nottingham, NG5 1PB, United Kingdom

Conditions

Explore the condition pages connected to this study.